Seaport Therapeutics Quarterly Cash Flow Statement
NASDAQ: SPTXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
18.15+0.24 (+1.34%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Seaport Therapeutics free cash flow
In the quarter ended Jun 30, 2026, Seaport Therapeutics generated -$26.1 million of operating cash flow and spent $0 on capital expenditures. That left free cash flow of -$26.1 million.
Summary generated from market data by MetaCap's automated system. Methodology
Seaport Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q? 20252025-06-30 | Q? 20252025-03-31 |
|---|---|---|---|---|
| Net Income | -62.60M | -25.41M | -15.08M | -13.13M |
| Net Income growth (YoY) | — | — | — | — |
| Depreciation & Amortization | 26.00K | 26.00K | 41.00K | 36.00K |
| Stock-Based Compensation | 36.86M | 2.57M | 1.76M | 1.62M |
| Change in Working Capital | 910.00K | 2.78M | -601.00K | -2.00M |
| Operating Cash Flow | -26.14M | -20.17M | -15.32M | -20.20M |
| Capital Expenditures | 0 | 0 | -269.00K | -54.00K |
| Investing Cash Flow | -203.50M | 27.85M | -1.44M | -225.55M |
| Financing Cash Flow | 240.93M | -783.00K | 0 | 0 |
| Net Change in Cash | 11.31M | 6.87M | -16.77M | -245.76M |
| Free Cash Flow | -26.14M | -20.17M | -15.59M | -20.26M |
This table shows 4 quarterly periods of Seaport Therapeutics's cash flow statement, from Q2 2026 back to Q? 2025, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow SPTX's reporting calendar. What is a cash flow statement?